Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$2.6b

Kymera Therapeutics Valuation

Is KYMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KYMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$110.00
Fair Value
63.2% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: KYMR ($40.45) is trading below our estimate of fair value ($110)

Significantly Below Fair Value: KYMR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KYMR?

Key metric: As KYMR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for KYMR. This is calculated by dividing KYMR's market cap by their current revenue.
What is KYMR's PS Ratio?
PS Ratio29.9x
SalesUS$87.56m
Market CapUS$2.55b

Price to Sales Ratio vs Peers

How does KYMR's PS Ratio compare to its peers?

The above table shows the PS ratio for KYMR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.4x
VCEL Vericel
12.9x20.4%US$2.9b
FOLD Amicus Therapeutics
5.8x18.7%US$2.9b
ACAD ACADIA Pharmaceuticals
3.3x8.7%US$3.1b
RARE Ultragenyx Pharmaceutical
7.7x32.3%US$3.9b
KYMR Kymera Therapeutics
29.9x35.1%US$2.6b

Price-To-Sales vs Peers: KYMR is expensive based on its Price-To-Sales Ratio (29.9x) compared to the peer average (7.4x).

Price to Sales Ratio vs Industry

How does KYMR's PS Ratio compare vs other companies in the US Biotechs Industry?

138 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.2x1.2%US$21.04b
MRNA Moderna
3.1x10.2%US$15.67b
INCY Incyte
3.5x5.4%US$14.20b
EXAS Exact Sciences
3.9x9.3%US$10.16b
KYMR 29.9xIndustry Avg. 10.1xNo. of Companies138PS01632486480+
138 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: KYMR is expensive based on its Price-To-Sales Ratio (29.9x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is KYMR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KYMR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.9x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: KYMR is expensive based on its Price-To-Sales Ratio (29.9x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KYMR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$40.45
US$58.84
+45.5%
18.7%US$97.00US$41.00n/a19
Jan ’26US$40.23
US$58.74
+46.0%
16.8%US$90.00US$41.00n/a19
Dec ’25US$46.85
US$57.76
+23.3%
19.9%US$90.00US$38.00n/a17
Nov ’25US$46.47
US$57.56
+23.9%
22.0%US$90.00US$38.00n/a16
Oct ’25US$46.57
US$55.88
+20.0%
30.1%US$106.00US$36.00n/a16
Sep ’25US$48.36
US$53.69
+11.0%
32.8%US$106.00US$33.00n/a16
Aug ’25US$44.49
US$51.13
+14.9%
39.4%US$112.00US$30.00n/a15
Jul ’25US$30.95
US$50.80
+64.1%
40.2%US$112.00US$30.00n/a15
Jun ’25US$32.11
US$50.80
+58.2%
40.2%US$112.00US$30.00n/a15
May ’25US$36.24
US$51.07
+40.9%
39.9%US$112.00US$30.00n/a15
Apr ’25US$39.42
US$50.93
+29.2%
41.4%US$112.00US$30.00n/a14
Mar ’25US$43.50
US$49.86
+14.6%
43.6%US$112.00US$30.00n/a14
Feb ’25US$32.68
US$43.00
+31.6%
55.7%US$112.00US$25.00n/a13
Jan ’25US$25.46
US$39.86
+56.5%
51.7%US$93.00US$16.00US$40.2314
Dec ’24US$20.77
US$41.73
+100.9%
50.6%US$93.00US$16.00US$46.8515
Nov ’24US$11.55
US$57.93
+401.5%
32.5%US$93.00US$31.00US$46.4714
Oct ’24US$13.90
US$56.53
+306.7%
33.5%US$93.00US$31.00US$46.5715
Sep ’24US$19.86
US$54.76
+175.8%
33.8%US$93.00US$31.00US$48.3617
Aug ’24US$21.68
US$54.65
+152.1%
33.8%US$93.00US$31.00US$44.4917
Jul ’24US$22.99
US$54.65
+137.7%
33.8%US$93.00US$31.00US$30.9517
Jun ’24US$29.40
US$54.94
+86.9%
34.6%US$93.00US$31.00US$32.1116
May ’24US$31.48
US$55.63
+76.7%
33.4%US$93.00US$31.00US$36.2416
Apr ’24US$29.63
US$55.63
+87.7%
33.4%US$93.00US$31.00US$39.4216
Mar ’24US$32.07
US$55.63
+73.4%
33.4%US$93.00US$31.00US$43.5016
Feb ’24US$36.59
US$55.69
+52.2%
34.0%US$93.00US$31.00US$32.6816
Jan ’24US$24.96
US$56.81
+127.6%
35.6%US$93.00US$31.00US$25.4616
Analyst Price Target
Consensus Narrative from 19 Analysts
US$58.84
Fair Value
31.3% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 00:20
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kymera Therapeutics, Inc. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research
Tazeen AhmadBofA Global Research